Skip to main content

corvidia-logo

Corvidia Therapeutics Inc., a clinical stage biotechnology company, announced today the initiation of patient screening for a Phase 2b dose-finding study of ziltivekimab. Previously known as COR-001, ziltivekimab is a proprietary anti-interleukin-6 ligand monoclonal antibody (anti-IL6 mAb), targeting residual inflammatory cardiovascular risk in patients living with advanced chronic kidney disease (CKD).

{iframe}https://www.businesswire.com/news/home/20190613005101/en/Corvidia-Therapeutics-Initiates-Phase-2b-Dose-Finding-Study{/iframe}

Search

You have successfully subscribed to the newsletter

There was an error while trying to send your request. Please try again.

BioHealth Innovation will use the information you provide on this form to be in touch with you and to provide updates and marketing.